The use of proteomics to identify novel therapeutic targets for the treatment of disease
Moseley, F.L., Bicknell, K.A., Marber, M.S. and Brooks, G. (2007) The use of proteomics to identify novel therapeutic targets for the treatment of disease. Journal of Pharmacy and Pharmacology, 59 (5). pp. 609-628. ISSN 0022-3573
Full text not archived in this repository.
To link to this item DOI: 10.1211/jpp.59.5.0001
The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post-translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.